From: www.ecancer.tv on Tue, Aug 03 2010 2:09 PM

Dr Cornes speaks about an e-learning facility used to share information among oncologists in Asia. Experts give lessons in the radiotherapy best practices and these lessons are recorded and uploaded to the internet where they can be accessed by clinicians in remote areas. Dr Cornes discusses the ...

From: www.ecancer.tv on Tue, Aug 03 2010 2:09 PM

Dr Cornes discusses how the health service will cope with the costs associated with rapidly rising cancer rates. Dr Cornes speaks about the role clinicians can play, making sure patients are treated in a cost effective way and explains what resources are available for doctors to learn more about...

From: www.ecancer.tv on Tue, Aug 03 2010 7:06 AM

Dr Stephen Baylin speaks at an EHA 2010 press conference about the use of epigenetics to treat cancer. Dr Baylin explains what epigenetics is, talks about some epigenetic drugs that have been successful in treating myelodysplastic syndrome (MDS) and explains how administering these drugs at a lo...

From: www.ecancer.tv on Tue, Aug 03 2010 7:06 AM

Prof Gilles Salles speaks at an EHA 2010 press conference about the PRIMA study which has shown that retuximab 'maintenance' therapy after initial treatment of retuximab plus chemotherapy reduces the risk of follicular lymphoma recurrence by up to 50%. Prof Salles discusses the effects ...

From: www.ecancer.tv on Tue, Aug 03 2010 6:02 AM

Dr Michael Huo speaks at an EHA 2010 press conference about a phase III prospective study comparing the dabigatran etexilate 220mg with enoxaparin 40mg as treatments to prevent venous thromboembolism (VTE) after total hip replacement surgery. The study showed dabigatran etexilate was as effective...

From: www.ecancer.tv on Tue, Aug 03 2010 6:02 AM

Prof Robin Foà talks about the increasing importance of the annual EHA congress, not just within Europe but across the world. The 2010 Barcelona congress is the first to hold a joint symposium with the Japanese Society of Hematology. Prof Foà explains how this, in addition to the collaborative w...

From: www.ecancer.tv on Tue, Aug 03 2010 6:02 AM

Dr Lee speaks about the TOPICAL trial, a randomised phase III trial of erlotinib in chemotherapy-naive patients with advanced non-small cell lung cancer who are unsuitable for first-line chemotherapy. Erlotinib was shown to significantly increase progression free survival in female patients but ...

From: www.ecancer.tv on Mon, Jul 26 2010 1:11 PM

At the time of your diagnosis did you feel you had sufficient information to make informed decisions?Would it have been helpful to have been given information in a different way or format?Did anyone use tools to describe risk calculations/probabilities – did they help or hinder?

From: www.ecancer.tv on Mon, Jul 26 2010 1:11 PM

What are the implications of knowing you are a gene carrier and how can you be better supported?For the women in these clips, discovering that they were BRCA gene was almost by accident. Should more be done to highlight that there are potentially increased risks within families for certain speci...

From: www.ecancer.tv on Mon, Jul 26 2010 1:11 PM

If you had to pick one thing that you think would improve risk communication what would it be? How can we speed up the process of adoption of best practice?

From: www.ecancer.tv on Mon, Jul 26 2010 1:10 PM

Who are the health professionals generally involved in communicating genetic risk in your country? Does it vary and are they the right people?What do you think are the skills needed? How do we get people to be better communicators if 'cook book' manuals don’t work?

From: www.ecancer.tv on Mon, Jul 26 2010 1:10 PM

What advice or support about how to tell other members of your family about being a gene carrier were you given? What works well?

From: www.ecancer.tv on Mon, Jul 26 2010 6:46 AM

Prof Goldstone talks about the UKALL trials investigating treatment options for patients with ALL. These trials have compared allograft, the use of long term chemotherapy and chemotherapy followed by autologous transplantation. Prof Goldstone speaks about some of the results, outlines patient ri...

From: www.ecancer.tv on Mon, Jul 26 2010 6:46 AM

Dr Johnson talks about the communication skills workshop he chaired at EHA 2010 and explains how good communication skills benefit both clinicians and their patients.

From: www.ecancer.tv on Mon, Jul 26 2010 5:19 AM

Prof O’Brien discusses the idea he proposed at the 2010 EHA congress: 'Patients should be 'forced' to enter clinical trials in order to receive the latest medication'. Prof O'Brien speaks about the current low patient uptake in clinical trials, explains the benefits of h...

From: www.ecancer.tv on Fri, Jul 23 2010 11:57 AM

Professor Robert Coleman speaks about the side effects experienced by patients with cancer of the bone and discusses how denosumab, zoledronic acid or other bisphosphonates can reduce these. A recent study comparing zoledronic acid with clodronate as treatment for myeloma has shown that signific...

From: www.ecancer.tv on Fri, Jul 23 2010 11:57 AM

Professor Robert Coleman talks about zoledronic acid, other bisphosphonates and denosumab, the mechanism through which these drugs affect cancers and outlines concerns of potential side effects. Prof Coleman speaks about the possibility of using gene profiling to predict effectiveness and specul...

From: www.ecancer.tv on Fri, Jul 23 2010 11:57 AM

Peter Goodwin speaks to Professor Robert Coleman about targeted therapy, specifically treatment that targets bone metastases. Prof Coleman explains how metastases move to the bone in many cancers and talks about cancer cells lying dormant in bone marrow. Prof Coleman explains the effects denosum...

From: www.ecancer.tv on Fri, Jul 23 2010 7:24 AM

Prof Jesús San-Miguel talks about the progression in myeloma survival rates and the contributing factors. Data from a large randomised trial is showing that zoledronic acid compared to oral clodronate is superior in preventing skeletal complications and is associated with prolongation of survival...

From: www.ecancer.tv on Thu, Jul 22 2010 2:58 PM

Dr Goldstone talks about the UKALL trials investigating treatment options for patients with ALL. These trials have compared allograft, the use of long term chemotherapy and chemotherapy followed by autologous transplantation. Dr Goldstone speaks about some of the results, outlines patient risk a...